Neisvac-C

Tetanus toxoid, algeldrate, Neisseria meningitidis group C polysaccharide, the active ingredient in Neisvac-C, is a vaccine presented as a vaccine for intramuscular use. It is used to prevent tetanus and meningococcal disease caused by Neisseria meningitidis group C in individuals requiring immunization.

GNH USA supplies Neisvac-C as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Neisvac-C is a combined tetanus and meningococcal group C vaccine used to stimulate protective immunity against specific bacterial toxins and polysaccharides. - Tetanus: induces immunity against tetanus toxin, reducing the risk of tetanus infection. - Meningococcal group C disease: stimulates antibodies against the capsular polysaccharide of Neisseria meningitidis group C, preventing invasive disease. - Travel or outbreak immunization: administered as part of prophylactic schedules for travelers or during public health campaigns to control meningococcal group C outbreaks.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Low‑grade fever: transient temperature rise within 24‑48 hours. - Headache: mild headache following vaccination. - Fatigue or malaise: general feeling of tiredness. - Muscle aches: transient myalgia.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder with progressive weakness. - Seizures: uncommon convulsive episodes. - Severe hypotension: marked drop in blood pressure post‑injection. - Persistent high fever: fever lasting more than 48 hours. - Severe local reaction: extensive necrosis or ulceration at the injection site.

Neisvac-C should be administered after careful assessment of the individual's health status. - Hypersensitivity screening: avoid in persons with known severe allergy to any vaccine component. - Acute illness deferment: postpone vaccination in individuals with moderate or severe febrile illness. - Post‑vaccination observation: monitor for at least 15 minutes for immediate reactions. - Immunocompromised caution: response may be reduced; consult healthcare provider. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Neisvac-C may interact with other immunological agents or therapies. Major Interactions (Avoid): - Concurrent administration of other tetanus‑containing vaccines: may increase risk of hypersensitivity. - Live viral vaccines given within 4 weeks: may interfere with immune response. Moderate Interactions (Monitor Closely): - Immunoglobulin therapy: can reduce vaccine efficacy if given within 2 weeks. - Immunosuppressive drugs: may diminish antibody production, requiring serologic monitoring. - Antipyretics taken prophylactically: may mask early signs of adverse reactions.